BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 35277242)

  • 1. Emerging antiresorptive medications and their potential implications for dental surgeries.
    Aminoshariae A; Donaldson M; Horan M; Mackey SA; Kulild JC; Baur D
    J Am Dent Assoc; 2022 Jul; 153(7):649-658. PubMed ID: 35277242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O; Peter JU
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012432. PubMed ID: 35866376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review.
    Guirguis RH; Tan LP; Hicks RM; Hasan A; Duong TD; Hu X; Hng JYS; Hadi MH; Owuama HC; Matthyssen T; McCullough M; Canfora F; Paolini R; Celentano A
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
    Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
    Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
    Neal TW; Schlieve T
    J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress on medication-related osteonecrosis of the jaw].
    Wang QZ; Liu JY; Pan J
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2018 Oct; 36(5):568-572. PubMed ID: 30465354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis - A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso).
    Madeira M; Rocha AC; Moreira CA; Aguiar ÁMM; Maeda SS; Cardoso AS; de Moura Castro CH; D'Alva CB; Silva BCC; Ferraz-de-Souza B; Lazaretti-Castro M; Bandeira F; Torres SR
    Arch Endocrinol Metab; 2021 May; 64(6):664-672. PubMed ID: 34033275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication-related osteonecrosis of the jaw: A multifaceted diagnostic challenge. Mini review.
    Bonachea R; Katz J
    Am J Dent; 2022 Apr; 35(2):109-112. PubMed ID: 35506967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
    Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.
    Di Fede O; Panzarella V; Mauceri R; Fusco V; Bedogni A; Lo Muzio L; Sipmo Onj Board ; Campisi G
    Biomed Res Int; 2018; 2018():2684924. PubMed ID: 30306086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.